mebufotenin
mebufotenin benzoate · BPL-003 Small Molecule Target: 5-HT1A, 5-HT2A
Atai Beckley
Most recent annual filing: 2026-03-06
- Merger partnership3Q 2026Merger partnership, 3Q 2026, routine
- VLS-01 topline4Q 2026VLS-01 topline, 4Q 2026, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
dimethyltryptamine
DMT · VLS-01 Small Molecule Target: 5-HT1, 5-HT2, 5-HT6, 5-HT7
R-MDMA
EMP-01 Small Molecule Target: 5-HT2A
EGX-A
EGX-B Small Molecule Target: 5-HT2A, 5-HT2C
Biotech Distilled coverage (10)
- 2026-07-16 UPDATE: AtaiBeckley (ATAI) — Lilly Buys the Thesis for $2.8B + CVRs 🔒 Paid
- 2026-07-06 UPDATE: AtaiBeckley (ATAI) - VLS-01 Graduates from Hedge to Second Pillar 🔒 Paid
- 2026-05-12 UPDATE: AtaiBeckley (ATAI) - The Phase 3 Blueprint, Decoded 🔒 Paid
- 2026-04-27 UPDATE: AtaiBeckley (ATAI) - Two Data Drops, One 38% Rally, and the Phase 3 Clock Ticking 🔒 Paid
- 2026-03-29 UPDATE: Atai Beckley (ATAI) - The Index Effect Takes Hold Ahead of Q2
- 2026-03-22 UPDATE: Atai Beckley (ATAI) - BPL-003 Gets Peer-Reviewed Validation as Phase 3 Approaches 🔒 Paid
- 2026-03-07 UPDATE: Atai Beckley (ATAI) - FDA Greenlights BPL-003 Phase 3; 10-K Confirms 2029 Runway 🔒 Paid
- 2026-02-28 UPDATE: Atai Beckley (ATAI) - EMP-01 Delivers a Phase 2a Win, But the Market Yawns 🔒 Paid
- 2026-01-11 UPDATE Atai Beckley (ATAI): JPM Update, Phase 3 Timelines, and Cash Runway to 2029 🔒 Paid
- 2025-12-24 Atai Beckley (ATAI): Scientific Due Diligence for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.